Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

HD5 Levels in Catheter Versus Bag Urine Specimens in Young Children for the Diagnosis of UTI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03163394
Recruitment Status : Terminated (Did not enroll enough patients for study)
First Posted : May 23, 2017
Last Update Posted : February 27, 2020
Sponsor:
Information provided by (Responsible Party):
Kristy Morse, Le Bonheur Children's Hospital

Tracking Information
First Submitted Date May 18, 2017
First Posted Date May 23, 2017
Last Update Posted Date February 27, 2020
Actual Study Start Date April 23, 2017
Actual Primary Completion Date June 10, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 19, 2017)
Sensitivity and specificity of HD5 as marker for UTI [ Time Frame: 1 year ]
The sensitivity and specificity of HD5 in determining urinary tract infections in bag versus catheter specimens in children aged 1 to 24 months
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title HD5 Levels in Catheter Versus Bag Urine Specimens in Young Children for the Diagnosis of UTI
Official Title HD5 Levels in Catheter Versus Bag Urine Specimens in Young Children for the Diagnosis of UTI
Brief Summary

Urinary tract infections (UTIs) are a common cause of bacteremia and serious bacterial infections in young children (2-24 months of age). Because these children are usually unable to say what symptoms they are experiencing, UTIs are diagnosed through testing. Current testing of urine samples require a catheter or suprapubic aspiration performed for urine collection for infections markers to be reliable. Bag specimens often have varying results that can be poor in sensitivity and specificity depending on what component of the urine test one is looking at. Catheter and aspiration testing can be anxiety-provoking to parents, be painful for patients and even introduce bacteria into the bladder. An antimicrobial peptide called alpha human defensin-5 (HD5) is produced by the uroepithelium in response to infection. HD5 has been studied in the urine and does increase in actual UTIs. This study will look at children 1 to 24 months of age and again study levels of HD5 in culture positive UTIs versus urine negative for UTI. This study will also determine if collection method alters HD5 levels. We will measure HD5 levels in the urine from a bag specimen and a catheter specimen in the same patient.

Our primary objective is to determine the sensitivity and specificity of HD5 measured in urine collected by bag and catheter in the same patient for the diagnosis of UTI in children between the age 1 to 24 months presenting with febrile illness and suspected UTI.

Detailed Description

Pediatric urinary tract infections (UTIs) are a common diagnosis and account for greater than 500,000 emergency department (ED) visits each year in the US. Although prevalence varies by age, gender, ethnicity and circumcision status, the overall prevalence is cited between 5% to 13.8%. UTIs also account for a large number of pediatric hospital admissions with up to 50,000 children admitted per year, 40% of which occurring in children under the age of 1 year. In children under the age of two, diagnosis of UTI is difficult as patients are unable to verbalize complaints and often present with only fever or other nonspecific symptoms such as vomiting. UTIs are the leading cause of occult bacteremia and serious bacterial infection in the 2-24 month age range.

A definitive diagnosis of UTI is made when a patient has pyuria and/or bacteriuria with a positive urine culture. For non-toilet trained children who have urine collected by either suprapubic aspiration (SPA) or bladder catheterization, a urine culture is considered positive if a single uropathogenic organism of at least 50,000 colony forming units (CFU) per mL is recovered. Identification of a uropathogen by culture can take up to 48 hours to be completed which delays treatment and risks progression of infection if antibiotics are not given empirically. Commonly, clinicians use urine microscopy and dipstick for quick diagnosis to enable early empiric treatment of UTIs. However, the components of the urinalysis are limited in sensitivity and specificity even for specimens of high quality such as those obtained by catheterization or suprapubic tap. The main components of urine dipstick testing are leukocyte esterase (LE) and nitrite levels in urine. The LE test has a sensitivity of 94% when combined with clinical suspicion for UTI, but a specificity of only 83%. False positives for UTI occur when LE is positive in the child who has pyuria for other reasons besides infection, for example, in urethritis or Kawasaki disease. False negatives can occur in young children because the pattern of more frequent urination allows less time to mount an adequate inflammatory response to bacteria. Nitrites have a low sensitivity in young children (53%) due to frequent voiding not allowing sufficient time (up to 4 hours) for production of nitrites by bladder-dwelling bacteria; however, specificity is high (98%) making this a good test to rule in UTI. Sensitivity and specificity of urine microscopy for WBCs and bacteria are worse than for LE with pyuria (5 or more WBC/high power field on a spun sample or >10 WBC/hpf on an un-spun sample) having a sensitivity and specificity of 73% and 81% respectively. Presence of bacteria on microscopy has a sensitivity and specificity of 81% and 83% respectively. The resulting over- and under-treatment for false positive and negative urinalyses leads to increased costs, antibiotic resistance and unnecessary adverse events from antibiotics. The inaccuracy of the traditional urinalysis on bagged urine samples is much greater than for catheter specimens. These specimens suffer from false positives results for leukocyte esterase and cultures at rates up to 75-88% because of contamination by urogenital flora and white blood cells present on the perineum.

As a result of the poor performance characteristics of routine urinalyses on bag specimens, a sample obtained by catheterization in children who are not yet toilet-trained is required even for UTI screening. This is invasive and painful for the child, causes anxiety for the family, leads to urethral trauma and can even introduce bacteria into the urinary system. Recent research describes a new two-step technique of obtaining urine samples of screening for UTI on these young patients. First, a bagged urine sample is taken, and if suspicious for UTI by urinalysis, the patient then is catheterized for culture. One study showed that this technique decreased the number of catheterizations by 33%; however, given the low specificity of the urinalyses on bag specimens, there is still substantial room for reductions in unnecessary bladder catheterizations.

New urinary biomarkers hold promise to improve screening accuracy for UTIs. Watson et al. investigated antimicrobial peptides (AMPs) as urinary biomarkers of UTIs in children. One specific AMP, derived from the epithelium, is human alpha-defensin 5 (HD5). This AMP is produced by intestinal Paneth cells, the female genital tract and the uroepithelium. HD5 was found to have mean concentration significantly higher in the urine from culture-positive compared to culture-negative specimens. When used in combination with LE, HD5 increased the specificity of the LE-only test by 6% without decreasing the sensitivity (97% for LE > trace). This study determined the optimal cut-off value of 174 pg/mg creatinine to declare sample positive. Because HD5 is not derived from white blood cells, its presence is not affected by the presence or absence of WBCs in the urine to accurately identify urinary inflammation. While the authors of this study examined results from both clean-catch and catheterized specimens, they did not analyze samples collected by both techniques from the same patient.

Identification and validation of biomarkers with improved performance characteristics could reduce over-treatment of UTIs; validating such biomarkers on bag urine specimens has the further benefit of reducing the need for catheterization to provide urine to screen for UTI in a relatively unselected population of young children who have fever without a focus. We propose to compare the use of HD5 in bag versus catheter urine samples on children 1 to 24 months of age to determine if the biomarker has similarly high sensitivity and specificity to the original study in both specimen types. Eliminating the need for urine culture would also save on costs for children whose rapid testing does not suggest UTI. Reducing the number of catheterizations performed on young children will decrease the number of painful procedures, prevent introduction of bacteria in the urinary tract and decrease parental anxiety.

Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Children between the age of 1 to 24 months that present to the LeBonheur Emergency Room with fever of 38.5 degrees Celsius by report or on measurement will have urine bag placed. If patient has urinalysis and urine culture ordered because of suspicion for UTI and patient has voided in the bag, then patient's family will be approached for research
Condition Urinary Tract Infections
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Terminated
Actual Enrollment
 (submitted: February 25, 2020)
5
Original Estimated Enrollment
 (submitted: May 19, 2017)
450
Actual Study Completion Date June 10, 2019
Actual Primary Completion Date June 10, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

Patient is between 1 to 24 months of age Patient has reported or measured fever >38.5 degrees C (101.3 degrees F)

Exclusion Criteria:

RSV Positive at time of urine collection Flu Positive at time of urine collection Known GU abnormality Neurogenic bladder Frequent catheterizations Indwelling catheter Antibiotics in the last 7 days

Sex/Gender
Sexes Eligible for Study: All
Ages 1 Month to 24 Months   (Child)
Accepts Healthy Volunteers Not Provided
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03163394
Other Study ID Numbers HD52017
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Kristy Morse, Le Bonheur Children's Hospital
Study Sponsor Le Bonheur Children's Hospital
Collaborators Not Provided
Investigators
Principal Investigator: Kristy Morse UTHSC
PRS Account Le Bonheur Children's Hospital
Verification Date February 2020